ABEO Relative Valuation
ABEO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ABEO is overvalued; if below, it's undervalued.
Historical Valuation
Abeona Therapeutics Inc (ABEO) is now in the Fair zone, suggesting that its current forward PS ratio of 3.78 is considered Fairly compared with the five-year average of -0.23. The fair price of Abeona Therapeutics Inc (ABEO) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：5.22
Fair
-8.63
PE
1Y
3Y
5Y
0.00
EV/EBITDA
Abeona Therapeutics Inc. (ABEO) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-3.38
EV/EBIT
Abeona Therapeutics Inc. (ABEO) has a current EV/EBIT of -3.38. The 5-year average EV/EBIT is -1.78. The thresholds are as follows: Strongly Undervalued below -6.35, Undervalued between -6.35 and -4.07, Fairly Valued between 0.50 and -4.07, Overvalued between 0.50 and 2.79, and Strongly Overvalued above 2.79. The current Forward EV/EBIT of -3.38 falls within the Historic Trend Line -Fairly Valued range.
3.78
PS
Abeona Therapeutics Inc. (ABEO) has a current PS of 3.78. The 5-year average PS is 175.01. The thresholds are as follows: Strongly Undervalued below -334.71, Undervalued between -334.71 and -79.85, Fairly Valued between 429.88 and -79.85, Overvalued between 429.88 and 684.74, and Strongly Overvalued above 684.74. The current Forward PS of 3.78 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Abeona Therapeutics Inc. (ABEO) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.93. The thresholds are as follows: Strongly Undervalued below -5.65, Undervalued between -5.65 and -3.29, Fairly Valued between 1.43 and -3.29, Overvalued between 1.43 and 3.78, and Strongly Overvalued above 3.78. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Abeona Therapeutics Inc. (ABEO) has a current P/FCF of 0.00. The 5-year average P/FCF is 13.93. The thresholds are as follows: Strongly Undervalued below -137.19, Undervalued between -137.19 and -61.63, Fairly Valued between 89.48 and -61.63, Overvalued between 89.48 and 165.04, and Strongly Overvalued above 165.04. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Abeona Therapeutics Inc (ABEO) has a current Price-to-Book (P/B) ratio of 1.62. Compared to its 3-year average P/B ratio of 3.09 , the current P/B ratio is approximately -47.44% higher. Relative to its 5-year average P/B ratio of 2.41, the current P/B ratio is about -32.60% higher. Abeona Therapeutics Inc (ABEO) has a Forward Free Cash Flow (FCF) yield of approximately -28.62%. Compared to its 3-year average FCF yield of -36.22%, the current FCF yield is approximately -20.99% lower. Relative to its 5-year average FCF yield of -72.83% , the current FCF yield is about -60.70% lower.
1.62
P/B
Median3y
3.09
Median5y
2.41
-28.62
FCF Yield
Median3y
-36.22
Median5y
-72.83
Competitors Valuation Multiple
The average P/S ratio for ABEO's competitors is 1.49, providing a benchmark for relative valuation. Abeona Therapeutics Inc Corp (ABEO) exhibits a P/S ratio of 3.78, which is 153.92% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ABEO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ABEO in the past 1 year is driven by Unknown.
People Also Watch
BPRN
Princeton Bancorp Inc
34.04USD
0.27%
RCEL
AVITA Medical Inc
3.42USD
-1.44%
ARAY
Accuray Inc
0.8893USD
0.34%
LAZR
Luminar Technologies Inc
0USD
-15.39%
SVRE
Saverone 2014 Ltd
1.32USD
-3.65%
TVGN
Tevogen Bio Holdings Inc
0.3491USD
-2.79%
CHMG
Chemung Financial Corp
54.94USD
-0.09%
VUZI
Vuzix Corp
3.51USD
-1.68%
ELLO
Ellomay Capital Ltd
27.05USD
1.69%
KFS
Kingsway Financial Services Inc
12.47USD
1.22%
Frequently Asked Questions
Is Abeona Therapeutics Inc (ABEO) currently overvalued or undervalued?
Abeona Therapeutics Inc (ABEO) is now in the Fair zone, suggesting that its current forward PS ratio of 3.78 is considered Fairly compared with the five-year average of -0.23. The fair price of Abeona Therapeutics Inc (ABEO) is between to according to relative valuation methord.
What is Abeona Therapeutics Inc (ABEO) fair value?
ABEO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Abeona Therapeutics Inc (ABEO) is between to according to relative valuation methord.
How does ABEO's valuation metrics compare to the industry average?
The average P/S ratio for ABEO's competitors is 1.49, providing a benchmark for relative valuation. Abeona Therapeutics Inc Corp (ABEO) exhibits a P/S ratio of 3.78, which is 153.92% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Abeona Therapeutics Inc (ABEO) as of Jan 07 2026?
As of Jan 07 2026, Abeona Therapeutics Inc (ABEO) has a P/B ratio of 1.62. This indicates that the market values ABEO at 1.62 times its book value.
What is the current FCF Yield for Abeona Therapeutics Inc (ABEO) as of Jan 07 2026?
As of Jan 07 2026, Abeona Therapeutics Inc (ABEO) has a FCF Yield of -28.62%. This means that for every dollar of Abeona Therapeutics Inc’s market capitalization, the company generates -28.62 cents in free cash flow.
What is the current Forward P/E ratio for Abeona Therapeutics Inc (ABEO) as of Jan 07 2026?
As of Jan 07 2026, Abeona Therapeutics Inc (ABEO) has a Forward P/E ratio of -8.63. This means the market is willing to pay $-8.63 for every dollar of Abeona Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Abeona Therapeutics Inc (ABEO) as of Jan 07 2026?
As of Jan 07 2026, Abeona Therapeutics Inc (ABEO) has a Forward P/S ratio of 3.78. This means the market is valuing ABEO at $3.78 for every dollar of expected revenue over the next 12 months.